Evidence map›Paper›PMID 25480945›Full record

ArticleCancer research2015

Identification of a functional SNP in the 3'UTR of CXCR2 that is associated with reduced risk of lung cancer.

Bríd M Ryan, Ana I Robles, Andrew C McClary, Majda Haznadar, Elise D Bowman, Sharon R Pine, Derek Brown, Mohammed Khan, Kouya Shiraishi, Takashi Kohno and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Association between polymorphisms in CXCR2 gene and preeclampsia.Molecular genetics & genomic medicine · 2019
    Article
  13. Article
  14. Article
  15. Article
  16. Chemokine Receptor 2 (Mediators of inflammation · 2019
    Article
  17. Article
  18. Article
  19. Article
  20. Genetic polymorphisms in theCancer management and research · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Bríd M RyanLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Ana I RoblesLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Andrew C McClaryLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. Department of Pathology, Stanford University Hospital and Clinics, Stanford, California.
Majda HaznadarLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Elise D BowmanLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Sharon R PineRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey.
Derek BrownLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Mohammed KhanLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Kouya ShiraishiDivision of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Hirokazu OkayamaLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Ramakrishna ModaliBioServe Ltd., Beltsville, Maryland.
Jun YokotaDivision of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Curtis C HarrisLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. Curtis_Harris@nih.gov.
National Cancer Institute · USNational Cancer Research Institute · GBBeltsville Agricultural Research Center · USRutgers, The State University of New Jersey · USStanford Health Care · US

Funding

Inflammatory Biomarkers of Diagnosis and Prognosis in Early Stage Lung CancerZIABC011557 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RYAN, BRID · 2014 to 2016
$653k
Intramural NIH HHS ZIA BC011557
6 · The paper itself

Abstract

Global changes in gene expression accompany the development of cancer. Thus, inherited variants in miRNA-binding sites are likely candidates for conferring inherited susceptibility. Using an in silico approach, we compiled a comprehensive list of SNPs predicted to modulate miRNA binding in genes from several key lung cancer pathways. We then investigated whether these SNPs were associated with lung cancer risk in two independent populations. In general, SNPs in miRNA-binding sites are rare. However, some allelic variation was observed. We found that rs1126579 in CXCR2 was associated with a reduced risk of lung cancer in both European American [ORTT vs. CC 0.56 (0.37-0.88); P = 0.008] and Japanese [ORTT vs. CC 0.62 (0.38-1.00); P = 0.049] populations. Furthermore, we found that the SNP disrupted a novel binding site for miR-516a-3p, led to a moderate increase in CXCR2 mRNA and protein expression, and increased MAPK signaling. Moreover, analysis of rs1126579 with serum levels of IL8, its endogenous ligand, supported an interaction whereby rs1126579-T and high serum IL8 conferred synergistic protection from lung cancer. Our findings demonstrate a function for a 3'UTR SNP in modulating CXCR2 expression, signaling, and susceptibility to lung cancer.

Indexed as

3' Untranslated RegionsPolymorphism, Single NucleotideAgedAllelesBinding SitesCase-Control StudiesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenetic VariationGenotypeHumansInterleukin-8JapanLigandsLung Neoplasms3' Untranslated RegionsInterleukin-8LigandsMicroRNAsReceptors, Interleukin-8B

Identifiers

PMID25480945
PMCPMC4315715
OpenAlexW2001660399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.